The pharmacological blockade of TLR2 and TLR4 signaling by antagonistic antibodies or small molecule inhibitors (e.g., TAK-242 for TLR4) successfully reduced the disease severity in bacteria-induced sepsis mouse models 13-15. This evidence concerns the gene TLR4 and Sepsis.